Abstract: A wire tensioning apparatus and method tensions one or more wires by moving the tensioning function from a wire module to an apparatus external to the wire module. Within the wire module, the wire is placed between a movable member and a stationary member. Tension is placed on the wire and adjusted until the desired tension and/or vibrational frequency is met. Once the desired tension and/or vibrational frequency is met, the wire is clamped between the movable and stationary members within the wire module in order to maintain the achieved tension and/or vibrational frequency.

Abstract: A wire tensioning apparatus and method tensions one or more wires by moving the tensioning function from a wire module to an apparatus external to the wire module. Externally to the wire module, a wire is attached to a fixed end and a movable end. Tension is placed on the wire, and the tension in the wire or the vibrational frequency of the wire is detected and compared to a desired value. If the tension in, or the vibrational frequency of, the tensioned wire does not correspond to the desired value, the tension is further adjusted until the desired value is met. Once the desired tension or the vibrational frequency is met, the wire is secured in the wire module in order to maintain the achieved tension and/or vibrational frequency.

Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.

Abstract: A wire tensioning apparatus and method tensions one or more wires by moving the tensioning function from a wire module to an apparatus external to the wire module. Externally to the wire module, a wire is attached to a fixed end and a movable end. Tension is placed on the wire, and the tension in the wire or the vibrational frequency of the wire is detected and compared to a desired value. If the tension in, or the vibrational frequency of, the tensioned wire does not correspond to the desired value, the tension is further adjusted until the desired value is met. Once the desired tension or the vibrational frequency is met, the wire is secured in the wire module in order to maintain the achieved tension and/or vibrational frequency.

Abstract: A wire tensioning apparatus and method tensions one or more wires by moving the tensioning function from a wire module to an apparatus external to the wire module. Within the wire module, the wire is placed between a movable member and a stationary member. Tension is placed on the wire and adjusted until the desired tension and/or vibrational frequency is met. Once the desired tension and/or vibrational frequency is met, the wire is clamped between the movable and stationary members within the wire module in order to maintain the achieved tension and/or vibrational frequency.

Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.

Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.